NASDAQ: ARVNArvinas Inc Stock
$7.58+0.49 (+6.91%)
Updated Jun 12, 2026
ARVN Price
$7.58
Fair Value Price
N/A
Market Cap
$489.07M
52 Week Low
$6.06
52 Week High
$14.51
P/E
-2.38x
P/B
1.26x
P/S
7.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$89.40M
Earnings
-$221.30M
Gross Margin
100%
Operating Margin
-247.2%
Profit Margin
-247.5%
Debt to Equity
0.67
Operating Cash Flow
-$254M
Beta
1.4
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ARVN Overview
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARVN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARVN
Ranked#400 of 463
Ranked#400 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important ARVN news, forecast changes, insider trades & much more!
ARVN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARVN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARVN is good value based on its book value relative to its share price (1.26x), compared to the US Biotechnology industry average (4.85x)
P/B vs Industry Valuation
ARVN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ARVN due diligence checks available for Premium users.
Valuation
ARVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.38x
Industry
16.53x
Market
14.15x
ARVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.26x
Industry
4.85x
ARVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARVN's financial health
Profit margin
Revenue
$15.6M
Net Income
-$57.6M
Profit Margin
-369.2%
ARVN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ARVN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$647.5M
Liabilities
$260.7M
Debt to equity
0.67
ARVN's short-term assets ($630.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARVN's short-term assets ($630.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARVN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$69.2M
Investing
$13.7M
Financing
-$100.0k
ARVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARVN vs Biotech Stocks
Arvinas Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.